6 mg implantat

DRUG3 trials

Sponsors

UZ Leuven, Friedrich-Schiller-Universitaet Jena, Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Conditions

Early Breast CancerOligorecurrent hormone-sensitive prostate cancer patientsprostate cancer

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)

Active, not recruitingCTIS2022-502634-52-00

Friedrich-Schiller-Universitaet Jenaprostate cancer

Start: 2023-05-16Target: 280Updated: 2025-08-25

Phase 4

Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"

Not yet recruitingCTIS2025-522848-40-00

Fundacion Grupo Espanol De Investigacion En Cancer De MamaEarly Breast Cancer

Target: 74Updated: 2025-12-29